Blood Glucose Monitor Market - Global Forecast To 2030
商品番号 : SMB-90596
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年11月 |
| ページ数 | 302 |
| 図表数 | 360 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
血糖値モニター市場 – 製品タイプ（自己血糖測定、専門医療現場）、用途（糖尿病管理、健康・ウェルネスモニタリング）、検査部位（指先、上腕）、エンドユーザー（セルフケア／在宅ケア） – 2030年までの世界予測
世界の血糖値モニター市場は、予測期間中に9.1%のCAGRで成長し、2025年の165億米ドルから2030年には254億米ドルに達すると予測されています。
血糖値モニター市場は、人口動態、臨床、そして技術面の要因に牽引され、力強い成長が見込まれています。世界的な糖尿病罹患率の上昇、高齢化人口の増加、そして自己血糖測定への意識の高まりが相まって、血糖値測定機器の需要を継続的に押し上げています。持続血糖測定（CGM）、スマートフォンやウェアラブルデバイスとの連携、AIベースのデータ分析といった技術の進歩により、精度、利便性、そして患者エンゲージメントが大幅に向上し、導入が加速しています。さらに、政府の支援策、医療インフラの改善、そして在宅モニタリングソリューションへのアクセス拡大も市場の成長を牽引しています。これらのトレンドは、今後数年間、先進国と新興国の両方で力強い勢いを維持すると予想されます。
本レポートは、血糖値測定器市場の分析を提供し、製品、アプリケーション、検査施設、地域、エンドユーザーなど、様々なセグメントにおける市場規模と将来の成長可能性の推定に重点を置いています。さらに、主要企業の競合分析も掲載しており、企業概要、製品・サービス内容、最近の動向、主要な市場戦略を詳細に解説しています。
本レポートは、血糖値測定器業界のマーケットリーダーおよび新規参入企業にとって貴重な洞察を提供し、市場全体とそのサブセグメントの概算収益数値を示しています。本レポートは、ステークホルダーが競争環境を理解し、事業のポジショニングを改善し、効果的な市場開拓戦略を策定するのに役立ちます。さらに、主要な市場促進要因、制約要因、課題、そして機会を浮き彫りにすることで、ステークホルダーが市場の現状を評価するのに役立ちます。
本レポートでは、以下の点について洞察を提供します。
主要な推進要因（糖尿病罹患率の増加、高齢者人口の増加と平均寿命の延伸、研究開発投資の増加と先進技術製品の投入、糖尿病以外のCGMの健康と予防への活用）、制約要因（血糖センサーへのアクセスにおける高コストと社会経済的格差、センサー寿命の短さと頻繁な交換）、機会（デジタルヘルスプラットフォームやスマートデバイスとの統合、CGMの適用範囲と償還ポリシーの拡大）、課題（非侵襲性血糖モニタリング技術の規制遵守上の課題、データ過多とアラーム疲れ）の分析。
- 市場浸透：世界の血糖値モニター市場における主要企業が提供する製品ポートフォリオに関する詳細な情報を提供します。本レポートは、製品タイプ、用途、検査施設、エンドユーザー、地域など、様々なセグメントを網羅しています。
- 製品の強化／イノベーション：世界の血糖値モニター市場における新製品の発売と予想されるトレンドに関する包括的な詳細情報を提供します。
- 市場開発：製品タイプ、用途、検査施設、エンドユーザー、地域別に、収益性の高い成長市場に関する詳細な知識と分析を提供します。
- 市場の多様化：世界の血糖値モニター市場における新製品、拡大市場、現在の進歩、投資に関する包括的な情報を提供します。
- 競合評価：世界の血糖値モニター市場における主要競合他社の市場シェア、成長計画、製品・サービスの提供、および能力に関する徹底的な評価を提供します。
Report Description
The global blood glucose monitor market is projected to reach 25.4 billion in 2030 from USD 16.5 billion in 2025, at a CAGR of 9.1% during the forecast period.
The market for blood glucose monitors is expected to grow strongly, driven by demographic, clinical, and technological factors. The rising global prevalence of diabetes, coupled with an expanding geriatric population and increasing awareness of self-monitoring, continues to fuel demand for blood glucose monitoring devices. Technological advancements, including continuous glucose monitoring (CGM), integration with smartphones and wearables, and AI-based data analytics, have significantly improved accuracy, convenience, and patient engagement, thereby accelerating adoption. Furthermore, supportive government initiatives, improved healthcare infrastructure, and expanding access to home-based monitoring solutions are contributing to market growth. These trends are expected to sustain robust momentum across both developed and emerging economies in the coming years.
Based on product type, the self-monitoring blood glucose systems segment accounted for the largest share in the blood glucose monitor market in 2024.
Based on product type, the global blood glucose monitor market is divided into four main segments: self-monitoring blood glucose systems, continuous glucose monitoring systems, professional point-of-care devices, and non-invasive products. Among these, self-monitoring blood glucose (SMBG) systems have gained the highest adoption due to their optimal balance between accuracy, comfort, and convenience for patients, particularly those managing their condition at home. These devices offer quick and reliable glucose readings with minimal discomfort, encouraging consistent self-monitoring practices. Additionally, advancements such as micro-needle lancets, smaller sample requirements, and improved test strip designs have enhanced their usability. Their compatibility with connected health ecosystems—including smartphone apps, cloud-based data tracking, and telehealth integration—further drives patient engagement and improves healthcare provider oversight. Growing patient preference for affordable, easy-to-use monitoring tools, combined with rising awareness of proactive diabetes management, continues to reinforce the dominance of the SMBG segment across both developed and developing markets.
Based on application, the diabetes management segment is expected to grow at the highest CAGR during the forecast period in the blood glucose monitor market.
The global blood glucose monitor market is segmented by application into three categories: diabetes management, health & wellness monitoring, and other applications. Among these, the diabetes management segment is projected to witness the fastest growth during the forecast period, driven by the rising prevalence of type 1 and type 2 diabetes and the growing need for continuous and precise glucose tracking. The increasing adoption of continuous glucose monitoring (CGM) systems, which offer real-time insights, has enabled improved insulin dosing, dietary management, and lifestyle optimization. The integration of monitoring devices with digital health platforms, mobile applications, and cloud-based analytics enables remote consultations, automated alerts, and seamless data sharing with healthcare professionals, thereby supporting personalized diabetes care. Moreover, the growing emphasis on preventive healthcare, early disease detection, and supportive reimbursement programs is encouraging the adoption of regular monitoring. The availability of compact, user-friendly, and connected home monitoring devices empowers patients to independently manage their glucose levels, ensuring better compliance and reducing the risk of severe complications. Additionally, the rising consumer focus on health optimization and metabolic wellness is expanding the use of glucose monitors beyond traditional diabetes management, further amplifying market growth.
North America is expected to register the highest share of the blood glucose monitor market during the forecast period.
The global blood glucose monitor market is divided into six main regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries.
North America accounted for the largest share of the global blood glucose monitor market, driven by its advanced healthcare infrastructure, high diabetes prevalence, and strong adoption of digital health technologies. The region benefits from the widespread availability of continuous glucose monitoring (CGM) systems, favorable reimbursement frameworks, and increased awareness of diabetes management and preventive care. Moreover, the strong presence of leading market players, continuous product innovation, and strategic collaborations between healthcare providers and technology companies further reinforce North America’s leadership position. Rising healthcare expenditure, growing geriatric population, and the rapid integration of connected and AI-enabled glucose monitoring devices continue to support sustained market growth across the region.
A breakdown of the primary participants (supply side) for the blood glucose monitor market referred to in this report is provided below:
- By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%)
- By Designation: C-level Executives (20%), Directors (35%), and Others (45%)
- By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%)
Prominent players in the blood glucose monitor market include Abbott Laboratories (US), Dexcom, Inc. (US), Medtronic (Ireland), B.Braun SE (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Ascensia Diabetes Care Holdings AG (Switzerland), Senseonics (US), Nipro (Japan), Medical Technology and Devices S.p.A. (Italy), Terumo Corporation (Japan), i-SENS, Inc. (South Korea), Sinocare (China), Nemaura Medical Inc. (UK), ACON Laboratories, Inc. (US), LifeScan IP Holdings, LLC (US), Ultrahuman Healthcare Pvt Ltd. (India), LifePlus (US), Prodigy Diabetes Care, LLC (US), A. Menarini Diagnostics S.r.l (Italy), Beurer GmbH (Germany), Oura Health Oy (Finland), SD Biosensor, INC (South Korea), Agatsa (India), Rossmax International Ltd (US), and Medisana Gmbh (Germany).
Research Coverage
The report provides an analysis of the blood glucose monitor market, focusing on estimating the market size and potential for future growth across various segments, including products, applications, test sites, regions, and end users. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product & service offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report provides valuable insights for market leaders and new entrants in the blood glucose monitor industry, offering approximate revenue figures for the overall market and its subsegments. It assists stakeholders in understanding the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, enabling stakeholders to assess the current state of the market.
This report provides insights into the following pointers:
Analysis of key drivers (Increasing prevalence of diabetes, Growing elderly population and increasing life expectancy, Rise in R&D investments and launch of technologically advanced products, wellness & preventive use of CGMs beyond diabetes), restraints (High cost and socioeconomic disparities in access to blood glucose sensors, Short sensor lifespan and frequent replacements), opportunities (Integration with digital health platforms and smart devices, Expansion of coverage and reimbursement policies for CGMs) and challenges (Regulatory compliance challenges for non-invasive glucose monitoring technologies, Data overload & alarm fatigue).
- Market Penetration: It provides detailed information on the product portfolios offered by major players in the global blood glucose monitor market. The report covers various segments, including product type, application, test site, end user, and region.
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global blood glucose monitor market.
- Market Development: Thorough knowledge and analysis of the profitable rising markets by product type, application, test site, end user, and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global blood glucose monitor market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global blood glucose monitor market.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED & REGIONAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 31
1.4 CURRENCY 31
1.5 STAKEHOLDERS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 34
2.1.1.1 Key sources of secondary data 35
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 Key primary sources 36
2.1.2.2 Objectives of primary research 36
2.1.2.3 Key industry insights 37
2.1.2.4 Breakdown of primaries 37
2.2 MARKET SIZE ESTIMATION 38
2.2.1 TOP-DOWN APPROACH (BASED ON UTILIZATION RATE AND ADOPTION PATTERN) 41
2.3 DATA TRIANGULATION 44
2.4 RESEARCH LIMITATIONS 45
2.4.1 SCOPE-RELATED LIMITATIONS 45
2.4.2 METHODOLOGY-RELATED LIMITATIONS 45
2.5 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 BLOOD GLUCOSE MONITOR MARKET OVERVIEW 50
4.2 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE AND COUNTRY (2024) 51
4.3 BLOOD GLUCOSE MONITOR MARKET: GEOGRAPHICAL MIX 52
4.4 BLOOD GLUCOSE MONITOR MARKET: REGIONAL MIX (2025–2030) 52
4.5 BLOOD GLUCOSE MONITOR MARKET: DEVELOPED VS. DEVELOPING MARKETS 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing prevalence of diabetes 55
5.2.1.2 Growing elderly population and increasing life expectancy 55
5.2.1.3 Rise in R&D investments and launch of technologically advanced products 56
5.2.1.4 Wellness & preventive use of CGMs beyond diabetes 57
5.2.2 RESTRAINTS 58
5.2.2.1 High cost and socioeconomic disparities in access to blood glucose sensors 58
5.2.2.2 Short sensor lifespan and frequent replacements 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Integration with digital health platforms and smart devices 59
5.2.4 CHALLENGES 59
5.2.4.1 Regulatory and compliance challenges for non-invasive glucose monitoring technologies 59
5.2.4.2 Data overload & alarm fatigue 60
5.2.4.3 Financial burden and coverage gaps 60
5.3 UNMET NEEDS & WHITE SPACES 61
5.3.1 UNMET NEEDS IN BLOOD GLUCOSE MONITOR MARKET 61
5.3.2 WHITE SPACE OPPORTUNITIES 61
5.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
5.4.1 INTERCONNECTED MARKETS 62
5.4.2 CROSS-SECTOR OPPORTUNITIES 62
6 INDUSTRY TRENDS 63
6.1 PORTER’S FIVE FORCES ANALYSIS 63
6.1.1 THREAT OF NEW ENTRANTS 64
6.1.2 INTENSITY OF COMPETITIVE RIVALRY 64
6.1.3 BARGAINING POWER OF BUYERS 64
6.1.4 BARGAINING POWER OF SUPPLIERS 65
6.1.5 THREAT OF SUBSTITUTES 65
6.2 MACROECONOMIC OUTLOOK 66
6.2.1 INTRODUCTION 66
6.2.2 GDP TRENDS AND FORECAST 66
6.2.3 TRENDS IN DIABETES CARE INDUSTRY 68
6.2.4 TRENDS IN GLOBAL INSULIN DELIVERY SYSTEMS INDUSTRY 68
6.3 SUPPLY CHAIN ANALYSIS 69
6.4 VALUE CHAIN ANALYSIS 70
6.5 ECOSYSTEM ANALYSIS 71
6.5.1 ROLE IN ECOSYSTEM 72
6.6 PRICING ANALYSIS 73
6.6.1 AVERAGE SELLING PRICE OF BLOOD GLUCOSE MONITORS, BY PRODUCT, 2024 73
6.6.2 AVERAGE SELLING PRICE TREND OF SELF-MONITORING BLOOD GLUCOSE SYSTEMS, BY REGION, 2022–2024 74
6.6.3 PRODUCT PURCHASE CYCLE, BY PRODUCT SEGMENT 74
6.7 TRADE ANALYSIS 75
6.7.1 IMPORT DATA FOR HS CODE 9027, 2020–2024 75
6.7.2 EXPORT DATA FOR HS CODE 9027, 2020–2024 76
6.8 KEY CONFERENCES & EVENTS, 2025–2026 76
6.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
6.10 INVESTMENT & FUNDING SCENARIO 78
6.11 CASE STUDY ANALYSIS 78
6.11.1 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSOR 78
6.11.2 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 79
6.11.3 CASE STUDY 3: IMPROVING GLYCEMIC CONTROL WITH DEXCOM G6 CGM SYSTEM 79
6.12 IMPACT OF 2025 US TARIFFS ON BLOOD GLUCOSE MONITOR MARKET 79
6.12.1 INTRODUCTION 79
6.12.2 KEY TARIFF RATES 80
6.12.3 PRICE IMPACT ANALYSIS 81
6.12.4 IMPACT ON REGION 82
6.12.4.1 US 82
6.12.4.2 Europe 82
6.12.4.3 Asia Pacific 82
6.12.5 IMPACT ON END-USE INDUSTRIES 83
7 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL AND AI ADOPTION 84
7.1 KEY EMERGING TECHNOLOGIES 84
7.2 COMPLEMENTARY TECHNOLOGIES 84
7.2.1 BATTERY AND ENERGY HARVESTING INNOVATIONS 84
7.3 TECHNOLOGY/PRODUCT ROADMAP 85
7.3.1 SHORT TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 85
7.3.2 MID TERM (2027–2030) | EXPANSION & STANDARDIZATION 85
7.3.3 LONG TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 86
7.4 PATENT ANALYSIS 86
7.4.1 PATENT PUBLICATION TRENDS FOR BLOOD GLUCOSE MONITOR MARKET 86
7.4.2 TOP APPLICANTS (COMPANIES) OF BLOOD GLUCOSE MONITOR PATENTS 87
7.4.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN BLOOD GLUCOSE MONITOR MARKET 88
7.4.4 LIST OF MAJOR PATENTS 88
7.5 PIPELINE ANALYSIS 89
7.6 IMPACT OF AI/GEN AI ON BLOOD GLUCOSE MONITOR MARKET 90
7.6.1 TOP USE CASES AND MARKET POTENTIAL 90
7.6.2 TOP CASE STUDIES OF AI IMPLEMENTATION IN BLOOD GLUCOSE MONITOR MARKET 91
7.6.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 91
7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BLOOD GLUCOSE MONITOR MARKET 92
7.7 SUCCESS STORIES & REAL-WORLD APPLICATIONS 92
7.7.1 ABBOTT: FREESTYLE LIBRE 3—MINIATURIZED SENSOR WITH REAL-TIME CONNECTIVITY 92
7.7.2 DEXCOM: G7 SENSOR—ADVANCED ALGORITHM FOR ACCURATE AND FAST GLUCOSE READINGS 92
7.7.3 SENSEONICS: EVERSENSE E3—LONG-TERM IMPLANTABLE CGM WITH SMART ALERTS 92
8 TREATMENT & REGULATORY LANDSCAPE 93
8.1 REGIONAL REGULATIONS & COMPLIANCE 93
8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
8.1.2 REGULATORY STANDARDS 95
8.1.2.1 North America 95
8.1.2.1.1 US 95
8.1.2.1.2 Canada 95
8.1.2.2 Europe 95
8.1.2.3 Asia Pacific 96
8.1.2.3.1 China 96
8.1.2.3.2 Japan 96
8.1.2.3.3 India 96
8.1.2.4 Latin America 96
8.1.2.4.1 Brazil 96
8.1.2.4.2 Mexico 97
8.1.2.5 Middle East 97
8.1.2.6 Africa 97
8.2 EPIDEMIOLOGY OF DIABETES, BY KEY COUNTRY 97
8.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98
8.3.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN BLOOD GLUCOSE MONITOR MARKET 98
8.4 TREATMENT AND REGULATORY LANDSCAPE 99
8.4.1 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 99
9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
9.1 DECISION-MAKING PROCESS 100
9.2 KEY STAKEHOLDERS & BUYING CRITERIA 100
9.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
9.2.2 KEY BUYING CRITERIA 101
9.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
9.4 UNMET NEEDS OF END USERS 103
9.5 MARKET PROFITABILITY 103
9.5.1 REVENUE POTENTIAL 103
9.5.2 COST DYNAMICS 104
9.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 104
10 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE 105
10.1 INTRODUCTION 106
10.2 SELF-MONITORING BLOOD GLUCOSE SYSTEMS 106
10.2.1 GLUCOMETERS 108
10.2.1.1 Regulatory reinforcement and digital integration to drive advancements in market 108
10.2.2 TESTING STRIPS 110
10.2.2.1 Shift toward non-invasive methods for blood glucose monitoring to restrain market growth 110
10.2.3 LANCETS & LANCING DEVICES 112
10.2.3.1 Rising focus on reducing chances of infection to increase popularity of safety lancets 112
10.3 CONTINUOUS GLUCOSE MONITORING SYSTEMS 113
10.3.1 SENSORS 115
10.3.1.1 Technological advancements and expanding use in diabetes management to boost market growth 115
10.3.2 IMPLANTS 116
10.3.2.1 Rising demand for long-duration sensors offering extended lifespan and reduced replacement frequency to drive growth 116
10.3.3 TRANSMITTERS & RECEIVERS 118
10.3.3.1 Integration with smart monitoring systems and interoperable diabetes management platforms to fuel growth 118
10.4 PROFESSIONAL POINT-OF-CARE DEVICES 119
10.4.1 ADVANCING PATIENT CARE THROUGH DECENTRALIZED POINT-OF-CARE GLUCOSE MONITORING TO BOOST MARKET 119
10.5 NON-INVASIVE PRODUCTS 121
10.5.1 RISING PATIENT PREFERENCE FOR PAINLESS TECHNOLOGY TO FOSTER DEVELOPMENT AND ADOPTION IN FUTURE 121
11 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE 123
11.1 INTRODUCTION 124
11.2 FINGERTIP 124
11.2.1 HIGH ACCURACY ASSOCIATED WITH FINGERTIP TESTING TO SUPPORT MARKET GROWTH 124
11.3 UPPER ARM 125
11.3.1 RISE OF CONTINUOUS AND MINIMALLY INVASIVE MONITORING TECHNOLOGIES TO BOOST DEMAND FOR UPPER ARM TESTING 125
11.4 OTHER TEST SITES 127
12 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION 129
12.1 INTRODUCTION 130
12.2 DIABETES MANAGEMENT 130
12.2.1 TYPE 1 DIABETES 132
12.2.1.1 Intensive management needs associated with type 1 diabetes to boost adoption 132
12.2.2 TYPE 2 DIABETES 133
12.2.2.1 High prevalence of type 2 diabetes to drive market demand 133
12.3 HEALTH & WELLNESS MONITORING 135
12.3.1 EMERGING ROLE OF HEALTH & WELLNESS MONITORING FOR BLOOD GLUCOSE MONITORS TO DRIVE MARKET GROWTH 135
12.4 OTHER APPLICATIONS 136
13 BLOOD GLUCOSE MONITOR MARKET, BY END USER 138
13.1 INTRODUCTION 139
13.2 SELF/HOME CARE 139
13.2.1 CONVENIENT, COST-EFFECTIVE, AND FREQUENT MONITORING ASSOCIATED WITH HOME CARE SETTINGS TO DRIVE MARKET 139
13.3 HOSPITALS & CLINICS 140
13.3.1 STRATEGIC ADOPTION OF BLOOD GLUCOSE SENSORS IN HOSPITALS & CLINICS TO DRIVE MARKET VALIDATION AND GROWTH 140
13.4 OTHER END USERS 142
14 BLOOD GLUCOSE MONITOR MARKET, BY REGION 144
14.1 INTRODUCTION 145
14.2 NORTH AMERICA 146
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 146
14.2.2 US 150
14.2.2.1 US to account for largest share of North American blood glucose monitor market 150
14.2.3 CANADA 153
14.2.3.1 Rising government support to boost blood glucose monitor market in Canada 153
14.3 EUROPE 156
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 156
14.3.2 GERMANY 160
14.3.2.1 Germany to dominate European blood glucose monitor market 160
14.3.3 UK 163
14.3.3.1 Government support and research funding to drive blood glucose monitor market growth in UK 163
14.3.4 FRANCE 165
14.3.4.1 High insurance coverage and increasing affordability to support market growth 165
14.3.5 ITALY 168
14.3.5.1 Increasing government spending to drive market growth in Italy 168
14.3.6 SPAIN 171
14.3.6.1 High diabetes prevalence to drive market growth in Spain 171
14.3.7 REST OF EUROPE (ROE) 173
14.4 ASIA PACIFIC 176
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 176
14.4.2 CHINA 181
14.4.2.1 China to dominate Asia Pacific blood glucose monitor market 181
14.4.3 JAPAN 184
14.4.3.1 Rising aging population and high number of diabetes cases to drive market growth in Japan 184
14.4.4 INDIA 187
14.4.4.1 Rising diabetes cases and affordable local manufacturing to fuel insulin device demand in India 187
14.4.5 AUSTRALIA 190
14.4.5.1 Government subsidies to drive market 190
14.4.6 SOUTH KOREA 192
14.4.6.1 Rising diabetes cases across country to boost market 192
14.4.7 REST OF ASIA PACIFIC 195
14.5 LATIN AMERICA 198
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 198
14.5.2 BRAZIL 201
14.5.2.1 Brazil to account for largest share of Latin American blood glucose monitor market 201
14.5.3 MEXICO 204
14.5.3.1 Rising diabetes prevalence to drive market growth 204
14.5.4 REST OF LATIN AMERICA 207
14.6 MIDDLE EAST & AFRICA 210
14.6.1 INTERNATIONAL AID PROGRAMS AND GOVERNMENT-LED INITIATIVES FOR NON-COMMUNICABLE DISEASE MANAGEMENT TO FOSTER GROWTH 210
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 210
14.7 GCC COUNTRIES 213
14.7.1 RISING DIABETES PREVALENCE TO DRIVE MARKET IN GCC COUNTRIES 213
14.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 213
15 COMPETITIVE LANDSCAPE 217
15.1 INTRODUCTION 217
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 217
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET 218
15.3 REVENUE ANALYSIS, 2020–2024 219
15.4 MARKET SHARE ANALYSIS, 2024 219
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 221
15.5.1 STARS 221
15.5.2 EMERGING LEADERS 221
15.5.3 PERVASIVE PLAYERS 222
15.5.4 PARTICIPANTS 222
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 223
15.5.5.1 Company footprint 223
15.5.5.2 Region footprint 224
15.5.5.3 Product type footprint 225
15.5.5.4 Test site footprint 226
15.5.5.5 Application footprint 227
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 228
15.6.1 PROGRESSIVE COMPANIES 228
15.6.2 RESPONSIVE COMPANIES 228
15.6.3 DYNAMIC COMPANIES 228
15.6.4 STARTING BLOCKS 228
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 229
15.6.5.1 Detailed list of key startups/SMEs 229
15.6.5.2 Competitive benchmarking of key startups/SMEs 230
15.7 COMPANY VALUATION & FINANCIAL METRICS 231
15.7.1 FINANCIAL METRICS 231
15.7.2 COMPANY VALUATION 231
15.8 BRAND/PRODUCT COMPARISON 232
15.9 R&D EXPENDITURE OF KEY PLAYERS 233
15.10 COMPETITIVE SCENARIO 233
15.10.1 PRODUCT LAUNCHES & APPROVALS 233
15.10.2 DEALS 235
15.10.3 EXPANSIONS 236
15.10.4 OTHER DEVELOPMENTS 236
16 COMPANY PROFILES 238
16.1 KEY PLAYERS 238
16.1.1 ABBOTT LABORATORIES 238
16.1.1.1 Business overview 238
16.1.1.2 Products offered 239
16.1.1.3 Recent developments 240
16.1.1.3.1 Product launches & approvals 240
16.1.1.3.2 Deals 241
16.1.1.3.3 Expansions 242
16.1.1.3.4 Other developments 242
16.1.1.4 MnM view 242
16.1.1.4.1 Right to win 242
16.1.1.4.2 Strategic choices 243
16.1.1.4.3 Weaknesses & competitive threats 243
16.1.2 DEXCOM, INC. 244
16.1.2.1 Business overview 244
16.1.2.2 Products offered 245
16.1.2.3 Recent developments 245
16.1.2.3.1 Product launches & approvals 245
16.1.2.3.2 Deals 246
16.1.2.4 MnM view 247
16.1.2.4.1 Right to win 247
16.1.2.4.2 Strategic choices 247
16.1.2.4.3 Weaknesses & competitive threats 247
16.1.3 MEDTRONIC 248
16.1.3.1 Business overview 248
16.1.3.2 Products offered 249
16.1.3.3 Recent developments 250
16.1.3.3.1 Product approvals 250
16.1.3.3.2 Deals 250
16.1.3.3.3 Expansions 251
16.1.3.3.4 Other developments 251
16.1.3.4 MnM view 251
16.1.3.4.1 Right to win 251
16.1.3.4.2 Strategic choices 251
16.1.3.4.3 Weaknesses & competitive threats 252
16.1.4 SINOCARE 253
16.1.4.1 Business overview 253
16.1.4.2 Products offered 254
16.1.4.3 Recent developments 254
16.1.4.3.1 Product approvals 254
16.1.4.3.2 Deals 255
16.1.4.3.3 Other developments 255
16.1.4.4 MnM view 255
16.1.4.4.1 Right to win 255
16.1.4.4.2 Strategic choices 255
16.1.4.4.3 Weaknesses & competitive threats 256
16.1.5 ROCHE DIABETES CARE 257
16.1.5.1 Business overview 257
16.1.5.2 Products offered 258
16.1.5.3 Recent developments 259
16.1.5.3.1 Product launches & approvals 259
16.1.5.3.2 Expansions 259
16.1.5.4 MnM view 260
16.1.5.4.1 Right to win 260
16.1.5.4.2 Strategic choices 260
16.1.5.4.3 Weaknesses & competitive threats 260
16.1.6 B. BRAUN SE 261
16.1.6.1 Business overview 261
16.1.6.2 Products offered 262
16.1.7 I-SENS, INC. 263
16.1.7.1 Business overview 263
16.1.7.2 Products offered 264
16.1.7.3 Recent developments 264
16.1.7.3.1 Product approvals 264
16.1.7.3.2 Deals 265
16.1.8 SENSEONICS 266
16.1.8.1 Business overview 266
16.1.8.2 Products offered 267
16.1.8.3 Recent developments 267
16.1.8.3.1 Product launches & approvals 267
16.1.8.3.2 Deals 268
16.1.8.3.3 Other developments 268
16.1.9 ASCENSIA DIABETES CARE HOLDINGS AG 269
16.1.9.1 Business overview 269
16.1.9.2 Products offered 269
16.1.9.3 Recent developments 270
16.1.9.3.1 Product launches 270
16.1.9.3.2 Deals 270
16.1.10 NIPRO 272
16.1.10.1 Business overview 272
16.1.10.2 Products offered 273
16.1.10.3 Recent developments 273
16.1.10.3.1 Expansions 273
16.1.11 NEMAURA MEDICAL INC. 274
16.1.11.1 Business overview 274
16.1.11.2 Products offered 274
16.1.11.3 Recent developments 275
16.1.11.3.1 Other developments 275
16.1.12 MEDICAL TECHNOLOGY AND DEVICES S.P.A. 276
16.1.12.1 Business overview 276
16.1.12.2 Products offered 276
16.1.12.3 Recent developments 277
16.1.12.3.1 Deals 277
16.1.13 TERUMO CORPORATION 278
16.1.13.1 Business overview 278
16.1.13.2 Products offered 279
16.1.13.3 Recent developments 280
16.1.13.3.1 Deals 280
16.1.13.3.2 Expansions 280
16.1.13.3.3 Other developments 280
16.1.14 LIFESCAN IP HOLDINGS, LLC 281
16.1.14.1 Business overview 281
16.1.14.2 Products offered 281
16.1.14.3 Recent developments 282
16.1.14.3.1 Deals 282
16.2 OTHER PLAYERS 283
16.2.1 ACON LABORATORIES, INC. 283
16.2.2 LIFEPLUS 284
16.2.3 PRODIGY DIABETES CARE, LLC 285
16.2.4 ULTRAHUMAN HEALTHCARE PVT. LTD. 286
16.2.5 BEURER GMBH 287
16.2.6 OURA HEALTH OY 288
16.2.7 SD BIOSENSOR, INC. 289
16.2.8 A. MENARINI DIAGNOSTICS S.R.L 290
16.2.9 MEDISANA GMBH 291
16.2.10 AGATSA 292
16.2.11 ROSSMAX INTERNATIONAL LTD. 292
17 APPENDIX 293
17.1 DISCUSSION GUIDE 293
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 298
17.3 CUSTOMIZATION OPTIONS 300
17.4 RELATED REPORTS 300
17.5 AUTHOR DETAILS 301
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 32
TABLE 2 RISK ASSESSMENT: BLOOD GLUCOSE MONITOR MARKET 45
TABLE 3 BLOOD GLUCOSE MONITOR MARKET: PORTER’S FIVE FORCES ANALYSIS 63
TABLE 4 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 66
TABLE 5 BLOOD GLUCOSE MONITOR MARKET: ROLE IN ECOSYSTEM 72
TABLE 6 AVERAGE SELLING PRICE OF BLOOD GLUCOSE MONITORS, BY PRODUCT, 2024 73
TABLE 7 AVERAGE SELLING PRICE TREND OF SELF-MONITORING BLOOD GLUCOSE SYSTEMS, BY REGION, 2022–2024 74
TABLE 8 IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSAND) 75
TABLE 9 EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSAND) 76
TABLE 10 BLOOD GLUCOSE MONITOR MARKET: LIST OF KEY CONFERENCES & EVENTS, 2025–2026 76
TABLE 11 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSOR 78
TABLE 12 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 79
TABLE 13 CASE STUDY 3: MPROVING GLYCEMIC CONTROL WITH DEXCOM G6 CGM SYSTEM 79
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 80
TABLE 15 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR BLOOD GLUCOSE MONITOR PRODUCTS 81
TABLE 16 BLOOD GLUCOSE MONITOR MARKET: LIST OF MAJOR PATENTS 88
TABLE 17 UPCOMING AND PIPELINE PRODUCTS IN GLOBAL BLOOD GLUCOSE MONITOR MARKET 89
TABLE 18 TOP USE CASES AND MARKET POTENTIAL 90
TABLE 19 BLOOD GLUCOSE MONITOR MARKET: CASE STUDIES RELATED TO GEN AI IMPLEMENTATION 91
TABLE 20 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 91
TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 26 DIABETES PREVALENCE, BY KEY COUNTRY 98
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 100
TABLE 28 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 101
TABLE 29 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
TABLE 30 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 106
TABLE 31 COMPANIES OFFERING SELF-MONITORING BLOOD GLUCOSE (SMBG) SYSTEMS 107
TABLE 32 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 107
TABLE 33 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 34 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR GLUCOMETERS,
BY REGION, 2023–2030 (THOUSAND UNITS) 109
TABLE 35 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR GLUCOMETERS,
BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 36 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR TESTING STRIPS,
BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 37 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET FOR LANCETS & LANCING DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 38 COMPANIES OFFERING CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS 113
TABLE 39 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 114
TABLE 40 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 41 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS,
BY REGION, 2023–2030 (THOUSAND UNITS) 115
TABLE 42 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 43 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR IMPLANTS,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 44 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR TRANSMITTERS & RECEIVERS, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 45 COMPANIES OFFERING PROFESSIONAL POINT-OF-CARE DEVICES 120
TABLE 46 PROFESSIONAL POINT-OF-CARE DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 47 COMPANIES OFFERING NON-INVASIVE PRODUCTS 122
TABLE 48 NON-INVASIVE PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 49 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE, 2023–2030 (USD MILLION) 124
TABLE 50 BLOOD GLUCOSE MONITOR MARKET FOR FINGERTIP TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 51 BLOOD GLUCOSE MONITOR MARKET FOR UPPER ARM TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 52 BLOOD GLUCOSE MONITOR MARKET FOR OTHER TEST SITES, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 53 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 130
TABLE 54 BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 131
TABLE 55 BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 56 BLOOD GLUCOSE MONITOR MARKET FOR TYPE 1 DIABETES, BY COUNTRY,
2023–2030 (USD MILLION) 133
TABLE 57 BLOOD GLUCOSE MONITOR MARKET FOR TYPE 2 DIABETES, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 58 BLOOD GLUCOSE MONITOR MARKET FOR HEALTH & WELLNESS MONITORING,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 59 BLOOD GLUCOSE MONITOR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 60 BLOOD GLUCOSE MONITOR MARKET, BY END USER, 2023–2030 (USD MILLION) 139
TABLE 61 BLOOD GLUCOSE MONITOR MARKET FOR SELF/HOME CARE, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 62 BLOOD GLUCOSE MONITOR MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 63 BLOOD GLUCOSE MONITOR MARKET FOR OTHER END USER, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 64 BLOOD GLUCOSE MONITOR MARKET, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 65 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 66 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 148
TABLE 67 NORTH AMERICA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 148
TABLE 68 NORTH AMERICA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 148
TABLE 69 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 149
TABLE 70 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 149
TABLE 71 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 72 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 150
TABLE 73 US: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 151
TABLE 74 US: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 75 US: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 76 US: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 152
TABLE 77 US: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 152
TABLE 78 US: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 79 US: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 153
TABLE 80 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 154
TABLE 81 CANADA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 82 CANADA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 83 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 155
TABLE 84 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 155
TABLE 85 CANADA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 155
TABLE 86 CANADA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 156
TABLE 87 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 88 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 157
TABLE 89 EUROPE: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 90 EUROPE: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 91 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 158
TABLE 92 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 159
TABLE 93 EUROPE: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 94 EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 159
TABLE 95 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 160
TABLE 96 GERMANY: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 97 GERMANY: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 98 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 161
TABLE 99 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 162
TABLE 100 GERMANY: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 162
TABLE 101 GERMANY: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 162
TABLE 102 UK: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 163
TABLE 103 UK: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 163
TABLE 104 UK: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 164
TABLE 105 UK: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 164
TABLE 106 UK: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 164
TABLE 107 UK: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 165
TABLE 108 UK: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 165
TABLE 109 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 166
TABLE 110 FRANCE: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 111 FRANCE: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 112 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 167
TABLE 113 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 167
TABLE 114 FRANCE: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 115 FRANCE: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 168
TABLE 116 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 169
TABLE 117 ITALY: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 169
TABLE 118 ITALY: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 169
TABLE 119 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 170
TABLE 120 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 170
TABLE 121 ITALY: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 122 ITALY: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 171
TABLE 123 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 171
TABLE 124 SPAIN: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 172
TABLE 125 SPAIN: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 172
TABLE 126 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 172
TABLE 127 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 173
TABLE 128 SPAIN: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 173
TABLE 129 SPAIN: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 173
TABLE 130 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 174
TABLE 131 REST OF EUROPE: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 132 REST OF EUROPE: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 133 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 175
TABLE 134 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 175
TABLE 135 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 176
TABLE 136 REST OF EUROPE: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 176
TABLE 137 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 178
TABLE 138 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 178
TABLE 139 ASIA PACIFIC: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 140 ASIA PACIFIC: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 141 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 179
TABLE 142 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 180
TABLE 143 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 144 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 180
TABLE 145 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 181
TABLE 146 CHINA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 182
TABLE 147 CHINA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 182
TABLE 148 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 182
TABLE 149 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 183
TABLE 150 CHINA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 183
TABLE 151 CHINA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 183
TABLE 152 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 184
TABLE 153 JAPAN: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 185
TABLE 154 JAPAN: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 185
TABLE 155 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 185
TABLE 156 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 186
TABLE 157 JAPAN: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 158 JAPAN: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 186
TABLE 159 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 187
TABLE 160 INDIA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 161 INDIA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 162 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 188
TABLE 163 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 189
TABLE 164 INDIA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 165 INDIA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 189
TABLE 166 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 190
TABLE 167 AUSTRALIA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 168 AUSTRALIA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 169 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 191
TABLE 170 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 191
TABLE 171 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 172 AUSTRALIA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 192
TABLE 173 SOUTH KOREA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 193
TABLE 174 SOUTH KOREA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 175 SOUTH KOREA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 176 SOUTH KOREA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 194
TABLE 177 SOUTH KOREA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 194
TABLE 178 SOUTH KOREA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 179 SOUTH KOREA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 195
TABLE 180 REST OF ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 195
TABLE 181 REST OF ASIA PACIFIC: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 182 REST OF ASIA PACIFIC: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 183 REST OF ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 196
TABLE 184 REST OF ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 197
TABLE 185 REST OF ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 186 REST OF ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET, BY END USER, 2023–2030 (USD MILLION) 197
TABLE 187 LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 198
TABLE 188 LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 199
TABLE 189 LATIN AMERICA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 190 LATIN AMERICA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 191 LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 200
TABLE 192 LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 193 LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 194 LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 195 BRAZIL: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 202
TABLE 196 BRAZIL: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 202
TABLE 197 BRAZIL: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 198 BRAZIL: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 203
TABLE 199 BRAZIL: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 203
TABLE 200 BRAZIL: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 203
TABLE 201 BRAZIL: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 204
TABLE 202 MEXICO: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 204
TABLE 203 MEXICO: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 204 MEXICO: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 205 MEXICO: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 205
TABLE 206 MEXICO: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 206
TABLE 207 MEXICO: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT,
BY TYPE, 2023–2030 (USD MILLION) 206
TABLE 208 MEXICO: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 206
TABLE 209 REST OF LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 207
TABLE 210 REST OF LATIN AMERICA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 211 REST OF LATIN AMERICA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 212 REST OF LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE, 2023–2030 (USD MILLION) 208
TABLE 213 REST OF LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209
TABLE 214 REST OF LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 215 REST OF LATIN AMERICA: BLOOD GLUCOSE MONITOR MARKET, BY END USER, 2023–2030 (USD MILLION) 209
TABLE 216 MIDDLE EAST & AFRICA: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 211
TABLE 217 MIDDLE EAST & AFRICA: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 218 MIDDLE EAST & AFRICA: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 219 MIDDLE EAST & AFRICA: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE, 2023–2030 (USD MILLION) 212
TABLE 220 MIDDLE EAST & AFRICA: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212
TABLE 221 MIDDLE EAST & AFRICA: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 212
TABLE 222 MIDDLE EAST & AFRICA: BLOOD GLUCOSE MONITOR MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 223 GCC COUNTRIES: BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 214
TABLE 224 GCC COUNTRIES: SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 225 GCC COUNTRIES: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 226 GCC COUNTRIES: BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2023–2030 (USD MILLION) 215
TABLE 227 GCC COUNTRIES: BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 215
TABLE 228 GCC COUNTRIES: BLOOD GLUCOSE MONITOR MARKET FOR DIABETES MANAGEMENT, BY TYPE, 2023–2030 (USD MILLION) 216
TABLE 229 GCC COUNTRIES: BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2023–2030 (USD MILLION) 216
TABLE 230 STRATEGIES ADOPTED BY KEY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET, JANUARY 2022–SEPTEMBER 2025 218
TABLE 231 BLOOD GLUCOSE MONITOR MARKET: DEGREE OF COMPETITION 220
TABLE 232 BLOOD GLUCOSE MONITOR MARKET: REGION FOOTPRINT 224
TABLE 233 BLOOD GLUCOSE MONITOR MARKET: PRODUCT TYPE FOOTPRINT 225
TABLE 234 BLOOD GLUCOSE MONITOR MARKET: TEST SITE FOOTPRINT 226
TABLE 235 BLOOD GLUCOSE MONITOR MARKET: APPLICATION FOOTPRINT 227
TABLE 236 BLOOD GLUCOSE MONITOR MARKET: DETAILED LIST OF KEY STARTUPS/SMES 229
TABLE 237 BLOOD GLUCOSE MONITOR MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (1/2) 230
TABLE 238 BLOOD GLUCOSE MONITOR MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (2/2) 230
TABLE 239 BLOOD GLUCOSE MONITOR MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–SEPTEMBER 2025 233
TABLE 240 BLOOD GLUCOSE MONITOR MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025 235
TABLE 241 BLOOD GLUCOSE MONITOR MARKET: EXPANSIONS,
JANUARY 2022–SEPTEMBER 2025 236
TABLE 242 BLOOD GLUCOSE MONITOR MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 236
TABLE 243 ABBOTT LABORATORIES: COMPANY OVERVIEW 238
TABLE 244 ABBOTT LABORATORIES: PRODUCTS OFFERED 239
TABLE 245 ABBOTT LABORATORIES: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–SEPTEMBER 2025 240
TABLE 246 ABBOTT LABORATORIES: DEALS, JANUARY 2022–SEPTEMBER 2025 241
TABLE 247 ABBOTT LABORATORIES: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 242
TABLE 248 ABBOTT LABORATORIES: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 242
TABLE 249 DEXCOM, INC.: COMPANY OVERVIEW 244
TABLE 250 DEXCOM, INC.: PRODUCTS OFFERED 245
TABLE 251 DEXCOM, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–SEPTEMBER 2025 245
TABLE 252 DEXCOM, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 246
TABLE 253 MEDTRONIC: COMPANY OVERVIEW 248
TABLE 254 MEDTRONIC: PRODUCTS OFFERED 249
TABLE 255 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 250
TABLE 256 MEDTRONIC: DEALS, JANUARY 2022–SEPTEMBER 2025 250
TABLE 257 MEDTRONIC: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 251
TABLE 258 MEDTRONIC: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 251
TABLE 259 SINOCARE: COMPANY OVERVIEW 253
TABLE 260 SINOCARE: PRODUCTS OFFERED 254
TABLE 261 SINOCARE: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 254
TABLE 262 SINOCARE: DEALS, JANUARY 2022–SEPTEMBER 2025 255
TABLE 263 SINOCARE: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 255
TABLE 264 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 257
TABLE 265 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 258
TABLE 266 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS LAUNCHES & APPROVALS,
JANUARY 2022–SEPTEMBER 2025 259
TABLE 267 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 259
TABLE 268 B. BRAUN SE: COMPANY OVERVIEW 261
TABLE 269 B. BRAUN SE: PRODUCTS OFFERED 262
TABLE 270 I-SENS, INC.: COMPANY OVERVIEW 263
TABLE 271 I-SENS, INC.: PRODUCTS OFFERED 264
TABLE 272 I-SENS, INC.: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 264
TABLE 273 I-SENS, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 265
TABLE 274 SENSEONICS: COMPANY OVERVIEW 266
TABLE 275 SENSEONICS: PRODUCTS OFFERED 267
TABLE 276 SENSEONICS: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–SEPTEMBER 2025 267
TABLE 277 SENSEONICS: DEALS, JANUARY 2022–SEPTEMBER 2025 268
TABLE 278 SENSEONICS: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 268
TABLE 279 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW 269
TABLE 280 ASCENSIA DIABETES CARE HOLDINGS AG: PRODUCTS OFFERED 269
TABLE 281 ASCENSIA DIABETES CARE HOLDINGS AG: PRODUCT LAUNCHES,
JANUARY 2022–SEPTEMBER 2025 270
TABLE 282 ASCENSIA DIABETES CARE HOLDINGS AG: DEALS,
JANUARY 2022–SEPTEMBER 2025 270
TABLE 283 NIPRO: COMPANY OVERVIEW 272
TABLE 284 NIPRO: PRODUCTS OFFERED 273
TABLE 285 NIPRO: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 273
TABLE 286 NEMAURA MEDICAL INC.: COMPANY OVERVIEW 274
TABLE 287 NEMAURA MEDICAL INC.: PRODUCTS OFFERED 274
TABLE 288 NEMAURA MEDICAL INC.: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 275
TABLE 289 MEDICAL TECHNOLOGY AND DEVICES S.P.A.: COMPANY OVERVIEW 276
TABLE 290 MEDICAL TECHNOLOGY AND DEVICES S.P.A.: PRODUCTS OFFERED 276
TABLE 291 MEDICAL TECHNOLOGY AND DEVICES S.P.A.: DEALS,
JANUARY 2022–SEPTEMBER 2025 277
TABLE 292 TERUMO CORPORATION: COMPANY OVERVIEW 278
TABLE 293 TERUMO CORPORATION: PRODUCTS OFFERED 279
TABLE 294 TERUMO CORPORATION: DEALS, JANUARY 2022–SEPTEMBER 2025 280
TABLE 295 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 280
TABLE 296 TERUMO CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 280
TABLE 297 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW 281
TABLE 298 LIFESCAN IP HOLDINGS, LLC: PRODUCTS OFFERED 281
TABLE 299 LIFESCAN IP HOLDINGS, LLC: DEALS, JANUARY 2022–SEPTEMBER 2025 282
LIST OF FIGURES
FIGURE 1 BLOOD GLUCOSE MONITOR MARKET SEGMENTATION & REGIONAL SCOPE 30
FIGURE 2 YEARS CONSIDERED 31
FIGURE 3 BLOOD GLUCOSE MONITOR MARKET: RESEARCH DESIGN 34
FIGURE 4 BLOOD GLUCOSE MONITOR MARKET: KEY DATA FROM SECONDARY SOURCES 35
FIGURE 5 BLOOD GLUCOSE MONITOR MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDE) 36
FIGURE 6 BLOOD GLUCOSE MONITOR MARKET: KEY INDUSTRY INSIGHTS 37
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 38
FIGURE 9 BLOOD GLUCOSE MONITOR MARKET SIZE ESTIMATION 39
FIGURE 10 REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC PLC 39
FIGURE 11 BLOOD GLUCOSE MONITOR MARKET: REVENUE ANALYSIS OF TOP 5 COMPANIES (2024) 40
FIGURE 12 BLOOD GLUCOSE MONITOR MARKET: EPIDEMIC MODEL ANALYSIS 41
FIGURE 13 BLOOD GLUCOSE MONITOR MARKET: TOP-DOWN APPROACH 41
FIGURE 14 BLOOD GLUCOSE MONITORMARKET: CAGR PROJECTIONS (SUPPLY SIDE) (2024) 42
FIGURE 15 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BLOOD GLUCOSE MONITOR MARKET (2025–2030) 43
FIGURE 16 BLOOD GLUCOSE MONITOR MARKET: DATA TRIANGULATION 44
FIGURE 17 BLOOD GLUCOSE MONITOR MARKET, BY PRODUCT TYPE,
2025 VS. 2030 (USD MILLION) 46
FIGURE 18 BLOOD GLUCOSE MONITOR MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 47
FIGURE 19 BLOOD GLUCOSE MONITOR MARKET, BY TEST SITE,
2025 VS. 2030 (USD MILLION) 47
FIGURE 20 BLOOD GLUCOSE MONITOR MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 48
FIGURE 21 GEOGRAPHICAL SNAPSHOT OF BLOOD GLUCOSE MONITOR MARKET 49
FIGURE 22 INCREASING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE MONITOR MARKET TO DRIVE GROWTH 50
FIGURE 23 CHINA ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2024 51
FIGURE 24 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 52
FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2025–2030) 52
FIGURE 26 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 53
FIGURE 27 BLOOD GLUCOSE MONITOR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
FIGURE 28 HEALTHCARE EXPENDITURE AS PERCENTAGE OF GDP FOR
1995, 2005, 2014, AND 2024 57
FIGURE 29 BLOOD GLUCOSE MONITOR MARKET: PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 30 BLOOD GLUCOSE MONITOR MARKET: SUPPLY CHAIN ANALYSIS 69
FIGURE 31 BLOOD GLUCOSE MONITOR MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 32 BLOOD GLUCOSE MONITOR MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 33 BLOOD GLUCOSE MONITOR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
FIGURE 34 BLOOD GLUCOSE MONITOR MARKET: FUNDING AND NUMBER OF DEALS,
2021–2024 78
FIGURE 35 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR BLOOD GLUCOSE MONITORS (JANUARY 2015–APRIL 2025) 87
FIGURE 36 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR BLOOD GLUCOSE MONITOR PATENTS, 2015–2025 88
FIGURE 37 KEY FEATURES OF AI/GENERATIVE AI IN BLOOD GLUCOSE MONITOR MARKET 90
FIGURE 38 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 100
FIGURE 39 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 101
FIGURE 40 BLOOD GLUCOSE MONITOR MARKET: GEOGRAPHIC SNAPSHOT 145
FIGURE 41 NORTH AMERICA: BLOOD GLUCOSE MONITOR MARKET SNAPSHOT 147
FIGURE 42 ASIA PACIFIC: BLOOD GLUCOSE MONITOR MARKET SNAPSHOT 177
FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET, 2020–2024 219
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET (2024) 220
FIGURE 45 BLOOD GLUCOSE MONITOR MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 222
FIGURE 46 BLOOD GLUCOSE MONITOR MARKET: COMPANY FOOTPRINT 223
FIGURE 47 BLOOD GLUCOSE MONITOR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 229
FIGURE 48 EV/EBITDA OF KEY VENDORS 231
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 231
FIGURE 50 BLOOD GLUCOSE MONITOR MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 232
FIGURE 51 R&D EXPENDITURE OF KEY PLAYERS IN BLOOD GLUCOSE MONITOR MARKET, 2022–2024 233
FIGURE 52 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024) 239
FIGURE 53 DEXCOM, INC.: COMPANY SNAPSHOT (2024) 244
FIGURE 54 MEDTRONIC: COMPANY SNAPSHOT (2024) 249
FIGURE 55 SINOCARE: COMPANY SNAPSHOT (2024) 253
FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 258
FIGURE 57 B. BRAUN SE: COMPANY SNAPSHOT (2024) 262
FIGURE 58 I-SENS, INC: COMPANY SNAPSHOT (2024) 263
FIGURE 59 SENSEONICS: COMPANY SNAPSHOT (2024) 266
FIGURE 60 NIPRO: COMPANY SNAPSHOT (2024) 272
FIGURE 61 TERUMO CORPORATION: COMPANY SNAPSHOT (2024) 279
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11
- 鉄道試験市場規模、シェア、動向、2032年までの世界予測 2025-12-10